IINN VS NRBO Stock Comparison

PerformanceSentimentTechnicalsEarningsProfitVolatility
PerformanceSentimentTechnicalsEarningsProfitVolatility

Performance

IINN
10/100

IINN returned -8.60% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

NRBO
10/100

NRBO returned -68.60% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Sentiment

IINN
64/100

IINN had a bullish sentiment score of 63.94% across Twitter and StockTwits over the last 12 months. It had an average of 2.16 posts, 0.42 comments, and 2.10 likes per day.

NRBO

"Sentiment" not found for NRBO

Technicals

IINN
10/100

IINN receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

NRBO
10/100

NRBO receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Earnings

IINN
100/100

IINN has missed earnings 0 times in the last 20 quarters.

NRBO
26/100

NRBO has missed earnings 4 times in the last 20 quarters.

Profit

IINN
21/100

Out of the last 18 quarters, IINN has had 3 profitable quarters and has increased their profits year over year on 3 of them.

NRBO
10/100

Out of the last 20 quarters, NRBO has had 0 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

IINN
40/100

IINN has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

NRBO
57/100

NRBO has had a higher than average amount of volatility over the last 12 months giving it a score of 57 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares Summary

Nasdaq / IINN
Healthcare
Medical - Devices
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel.

NeuroBo Pharmaceuticals, Inc. Common Stock Summary

Nasdaq / NRBO
Healthcare
Biotechnology
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.